Free press releases distribution network?

Agency / Source: Metrics, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Stefan Cross Appointed President of Mayne Pharma USA - Cross will manage all U.S. operations, including contract services and pharmaceutical products -
Stefan Cross Appointed President of Mayne Pharma USA


PRZOOM - /newswire/ - Greenville, NC, United States, 2014/01/28 - Cross will manage all U.S. operations, including contract services and pharmaceutical products -

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Mayne Pharma Group Limited has named Stefan Cross as president of Mayne Pharma USA.

Cross is responsible for leading all of Mayne Pharma’s existing business operations in the United States, and for spearheading new business development initiatives.

Among those responsibilities includes managing the continued growth of contract pharmaceutical services as provided by Mayne Pharma’s subsidiary, Metrics Inc., and positioning it to become one of North America’s leading providers of solid oral dose formulation development and analytical support services. To that end, the company plans to make significant investments in Metrics’ fast-track, proof-of-concept, and first-time-in-man programs, potent and cytotoxic product handling, and clinical trial material manufacturing for contract services clients.

Cross also will oversee the expansion of Mayne Pharma USA’s pharmaceutical products division, which has been one of the fastest-growing U.S. generics businesses in recent years. This business established less than 10 years ago now markets more than 20 products and has 20 products under development with 10 ANDAs filed with the FDA. Cross will focus on expanding the U.S. product portfolio through both organic development and further bolt-on acquisitions.

Prior to this most recent promotion, Cross served as Mayne Pharma’s vice president of business and corporate development, and played a key role in the global commercialization of the company’s SUBACAP® anti-fungal product. He has been extensively involved in integrating Metrics with Mayne Pharma, and in executing the company’s business strategy in Australia and the United States since joining in 2012.

Cross brings more than 20 years of industry experience to his role. He previously headed marketing efforts in the Asia Pacific region for Hospira Inc., a leading global provider of pharmaceuticals and medical devices. He also led Hospira’s commercial operations in China, Hong Kong and Taiwan. Prior to that, Cross worked for six years with Mayne Pharma Limited in Europe and Australia, and eight years with F.H. Faulding & Co. Limited.

“Stefan has an impressive track record of success in the pharmaceutical industry and will add tremendous value to our U.S. business,” said Scott Richards, CEO of Mayne Pharma. “His breadth of experience covers commercial operations, marketing, product licensing, business strategy and M&A. I look forward to accelerating the growth of our U.S. businesses with Stefan’s support and leadership.”

Cross succeeds Phil Hodges, who founded Metrics Inc. almost two decades ago and recently retired as president of the company. Hodges serves on the board of directors of Mayne Pharma Group Limited.

About Mayne Pharma
Mayne Pharma is a publicly traded specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic product globally either directly or through distribution partners while applying its drug-delivery expertise for contract development and manufacturing services.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world.

Mayne Pharma has drug development and manufacturing facilities in Salisbury, Australia, with expertise in formulating complex oral dose forms, including controlled substances, modified release products and inherently unstable compounds.

About Mayne Pharma USA
Mayne Pharma USA consists of two main business segments that focus on contract pharmaceutical services and the development and manufacturing of branded and generic pharmaceutical products.

Through Mayne Pharma USA’s contract services subsidiary, Metrics Inc. (, the company offers pharmaceutical development and manufacturing services to clients worldwide. Areas of expertise include pharmaceutical formulation development; first-time-in-man formulations; clinical trial materials manufacturing for Phase I, II, and III trials; and analytical method development and validation services leading to commercial-scale manufacturing.

Capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which Mayne Pharma offers a vast portfolio of drug delivery methods.

Mayne Pharma USA also distributes a range of branded and generic pharmaceutical products through its subsidiaries that include Midlothian Inc. and Libertas Pharma.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Metrics, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Stefan Cross Appointed President of Mayne Pharma USA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Metrics, Inc. | Stefan Cross
Contact: Karen Stinneford - for Metrics 
919-833-9102 kys[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Metrics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Metrics, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  Demyk Lightmod Products, Inc.

Visit  NAKIVO, Inc.


  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today